Deepika Razia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deepika Razia has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Rajat Walia
Department of Thoracic Disease and Transplantation, Norton Thoracic Institute, Phoenix, USA
9 shared publications - Sofya Tokman
Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center Phoenix Arizona USA
7 shared publications - Ross M. Bremner
Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, USA
5 shared publications - Ashraf Omar
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona; Department of Medicine, Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, Arizona
4 shared publications - Ashwini Arjuna
Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, USA
4 shared publications - Hesham Mohamed
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States
3 shared publications
Latest Publications
- 16 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 442-452
Evolving impact of the COVID-19 pandemic on lung transplant recipients: A single-center experience
- 16 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 442-452
Evolving impact of the COVID-19 pandemic on lung transplant recipients: A single-center experience
- Open Access
- 1 March 2023
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 07 (01) , 1-13
Impact of Sex and Age at Lung Transplantation on Long-Term Survival of Patients with Cystic Fibrosis
Careful selection of lung transplant (LT) recipients with cystic fibrosis (CF) may improve outcomes; therefore, we studied the impact of sex and age at the time of LT on long-term survival of patients with CF. LT recipients with CF who received post-LT care at our center between July 1, 2007 and April 30, 2021 were included. The primary outcome was death or retransplantation. Cox proportional hazard analysis and the Kaplan-Meier method were used. Of 59 included LT recipients, the median age at first LT was 28 (22, 36) years, 36 (61%) patients were ≥25 years old, and 30 (51%) were male. At the end of the study, 21 (36%) had died and 17 (29%) had required retransplantation, with a median lung allograft survival of 33.4 (16.1, 66.4) months. The remaining 21 patients (36%) were alive at a median of 68 (28, 112) months after primary LT. The probability of survival of male patients trended higher than that of female patients (66.7% vs 44.8%, p = 0.069). Compared to age < 25 years at LT, age ≥ 25 years was associated with a significantly higher probability of survival (63.9% vs 43.5%, p = 0.047). LT recipients with CF aged ≥ 25 years at LT had significantly higher survival than younger patients, and survival trended higher for male recipients compared to female recipients. These results identify an at-risk population of LT recipients who may warrant closer attention after LT. Large multicenter trials with adequate power are needed.
- 1 March 2023
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 07 (01) , 1-13
Open AccessImpact of Sex and Age at Lung Transplantation on Long-Term Survival of Patients with Cystic Fibrosis
Careful selection of lung transplant (LT) recipients with cystic fibrosis (CF) may improve outcomes; therefore, we studied the impact of sex and age at the time of LT on long-term survival of patients with CF. LT recipients with CF who received post-LT care at our center between July 1, 2007 and April 30, 2021 were included. The primary outcome was death or retransplantation. Cox proportional hazard analysis and the Kaplan-Meier method were used. Of 59 included LT recipients, the median age at first LT was 28 (22, 36) years, 36 (61%) patients were ≥25 years old, and 30 (51%) were male. At the end of the study, 21 (36%) had died and 17 (29%) had required retransplantation, with a median lung allograft survival of 33.4 (16.1, 66.4) months. The remaining 21 patients (36%) were alive at a median of 68 (28, 112) months after primary LT. The probability of survival of male patients trended higher than that of female patients (66.7% vs 44.8%, p = 0.069). Compared to age < 25 years at LT, age ≥ 25 years was associated with a significantly higher probability of survival (63.9% vs 43.5%, p = 0.047). LT recipients with CF aged ≥ 25 years at LT had significantly higher survival than younger patients, and survival trended higher for male recipients compared to female recipients. These results identify an at-risk population of LT recipients who may warrant closer attention after LT. Large multicenter trials with adequate power are needed.
- Open Access
- 6 January 2023
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 07 (01) , 1-11
Lung Transplantation from A Donor with Previous SARS-CoV-2 Infection: 1-Year Outcomes
Few reports have described successful lung transplantation from a donor with a history of SARS-CoV-2 infection, and outcomes beyond 3 to 6 months remain unknown. After weighing the urgency and life-saving benefits of lung transplantation against the risk of viral transmission, we successfully performed a bilateral lung transplant from a donor with confirmed SARS-CoV-2 infection with mild symptoms 2 months before donation. At 1 year after transplant, there is no evidence of donor-derived viral transmission, and allograft function is excellent and stable, with FVC of 3.66 L (77% predicted) and FEV1 of 3.08 L (85% predicted). With careful selection, lung transplantation from a donor with a history of mild SARS-CoV-2 infection was performed safely, with good allograft survival.
- 6 January 2023
- Published by LIDSEN Publishing Inc in OBM Transplantation
- Vol. 07 (01) , 1-11
Open AccessLung Transplantation from A Donor with Previous SARS-CoV-2 Infection: 1-Year Outcomes
Few reports have described successful lung transplantation from a donor with a history of SARS-CoV-2 infection, and outcomes beyond 3 to 6 months remain unknown. After weighing the urgency and life-saving benefits of lung transplantation against the risk of viral transmission, we successfully performed a bilateral lung transplant from a donor with confirmed SARS-CoV-2 infection with mild symptoms 2 months before donation. At 1 year after transplant, there is no evidence of donor-derived viral transmission, and allograft function is excellent and stable, with FVC of 3.66 L (77% predicted) and FEV1 of 3.08 L (85% predicted). With careful selection, lung transplantation from a donor with a history of mild SARS-CoV-2 infection was performed safely, with good allograft survival.
- Open Access
- 22 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (2) , 255-263
Hospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease
- 22 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (2) , 255-263
Open AccessHospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease
- 29 August 2022
- Published by Elsevier in Transplant Immunology
- Vol. 75, 101703
Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients
- 29 August 2022
- Published by Elsevier in Transplant Immunology
- Vol. 75, 101703
Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients
- Open Access
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S434
Parvovirus B19: A Potential Cause of Refractory Leukopenia in Lung Transplant Recipients
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S434
Open AccessParvovirus B19: A Potential Cause of Refractory Leukopenia in Lung Transplant Recipients
- Open Access
- 3 March 2022
- Published by Wiley in Journal of Transplantation
- Vol. 2022, 1-8
Orthostatic Hypotension and Concurrent Autonomic Dysfunction: A Novel Complication of Lung Transplantation
Background. Persistent orthostatic hypotension (OH) is a lesser-known complication of lung transplantation (LTx). In this retrospective case series, we describe the clinical manifestations, complications, and treatment of persistent OH in 13 LTx recipients. Methods. We identified LTx recipients who underwent transplantation between March 1, 2018, and March 31, 2020, with persistent symptomatic OH and retrospectively queried the records for clinical information. Results. Thirteen patients were included in the analysis, 9 (69) had underlying pulmonary fibrosis, and 12 (92) were male. The median age, height, and body mass index at LTx were 68 years, 70 inches, and 27kg/m2, respectively. Six (46) patients were deceased at the time of chart abstraction with a median (IQR) posttransplant survival of 12.6 months (6, 21); the 7 remaining living patients were a median of 19.6 months (18, 32) posttransplant. Signs and symptoms of OH developed a median of 60 (7, 75) days after transplant. Patients were treated with pharmacological agents and underwent extensive physical therapy. Most patients required inpatient rehabilitation (n=10, 77), and patients commonly developed comorbid conditions including weight loss, renal insufficiency with eGFR n=13, 100), gastroparesis (n=7, 54), and tachycardia-bradycardia syndrome (n=2, 15). Falls were common (n=10, 77). The incidence of OH in LTx recipients at our center during the study period was 5.6 (13/234). Conclusions. Persistent OH is a lesser-known complication of LTx that impacts posttransplant rehabilitation and may lead to comorbidities and shortened survival. In addition, most LTx recipients with OH at our center were tall, thin men with underlying pulmonary fibrosis, which may offer an opportunity to instate pretransplant OH screening of at-risk patients.
- 3 March 2022
- Published by Wiley in Journal of Transplantation
- Vol. 2022, 1-8
Open AccessOrthostatic Hypotension and Concurrent Autonomic Dysfunction: A Novel Complication of Lung Transplantation
Background. Persistent orthostatic hypotension (OH) is a lesser-known complication of lung transplantation (LTx). In this retrospective case series, we describe the clinical manifestations, complications, and treatment of persistent OH in 13 LTx recipients. Methods. We identified LTx recipients who underwent transplantation between March 1, 2018, and March 31, 2020, with persistent symptomatic OH and retrospectively queried the records for clinical information. Results. Thirteen patients were included in the analysis, 9 (69) had underlying pulmonary fibrosis, and 12 (92) were male. The median age, height, and body mass index at LTx were 68 years, 70 inches, and 27kg/m2, respectively. Six (46) patients were deceased at the time of chart abstraction with a median (IQR) posttransplant survival of 12.6 months (6, 21); the 7 remaining living patients were a median of 19.6 months (18, 32) posttransplant. Signs and symptoms of OH developed a median of 60 (7, 75) days after transplant. Patients were treated with pharmacological agents and underwent extensive physical therapy. Most patients required inpatient rehabilitation (n=10, 77), and patients commonly developed comorbid conditions including weight loss, renal insufficiency with eGFR n=13, 100), gastroparesis (n=7, 54), and tachycardia-bradycardia syndrome (n=2, 15). Falls were common (n=10, 77). The incidence of OH in LTx recipients at our center during the study period was 5.6 (13/234). Conclusions. Persistent OH is a lesser-known complication of LTx that impacts posttransplant rehabilitation and may lead to comorbidities and shortened survival. In addition, most LTx recipients with OH at our center were tall, thin men with underlying pulmonary fibrosis, which may offer an opportunity to instate pretransplant OH screening of at-risk patients.
- Open Access
- 11 February 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (3) , e1294
Lung Transplant Candidates With Pretransplant Gastroesophageal Reflux and Antibodies to Lung Self-antigens Have Shorter CLAD-free Survival After Transplant
Background. Pre–lung transplant (LTx) gastroesophageal reflux (GER) and circulating antibodies against the lung self-antigens (SAbs) collagen V and K-alpha-1 tubulin may predispose recipients to chronic lung allograft dysfunction (CLAD). We aimed to study the association of pre-LTx GER or pre-LTx SAbs with CLAD. Methods. In this retrospective analysis of patients who underwent LTx between 2015 and 2019, pre-LTx GER and SAbs were dichotomously defined as present or absent. The study group comprised recipients with either GER‚ SAbs, or both, and the control group comprised recipients without GER or SAbs. Endpoints included CLAD and survival. Results. Ninety-five LTx recipients were divided into a study group (n = 71; 75%) and a control group (n = 24; 25%). Pretransplant GER was associated with pre-LTx SAbs (odds ratio [95% confidence intervals], 5.022 [1.419-17.770]; P = 0.012). In addition, the study group (either GER‚ SAbs, or both) had a higher risk of CLAD (hazard ratio [95% confidence intervals], 8.787 [1.694-45.567]; P = 0.010) and lower CLAD-free survival after LTx than the control group (P = 0.007); however, overall survival was similar between the 2 groups (P = 0.618). Conclusions. GER was associated with elevated SAbs in LTx candidates, and either GER, SAbs, or both were associated with CLAD in LTx recipients. This association suggests that GER may cause an immune response to normally sequestered lung-associated self-antigens that drives ongoing lung injury.
- 11 February 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (3) , e1294
Open AccessLung Transplant Candidates With Pretransplant Gastroesophageal Reflux and Antibodies to Lung Self-antigens Have Shorter CLAD-free Survival After Transplant
Background. Pre–lung transplant (LTx) gastroesophageal reflux (GER) and circulating antibodies against the lung self-antigens (SAbs) collagen V and K-alpha-1 tubulin may predispose recipients to chronic lung allograft dysfunction (CLAD). We aimed to study the association of pre-LTx GER or pre-LTx SAbs with CLAD. Methods. In this retrospective analysis of patients who underwent LTx between 2015 and 2019, pre-LTx GER and SAbs were dichotomously defined as present or absent. The study group comprised recipients with either GER‚ SAbs, or both, and the control group comprised recipients without GER or SAbs. Endpoints included CLAD and survival. Results. Ninety-five LTx recipients were divided into a study group (n = 71; 75%) and a control group (n = 24; 25%). Pretransplant GER was associated with pre-LTx SAbs (odds ratio [95% confidence intervals], 5.022 [1.419-17.770]; P = 0.012). In addition, the study group (either GER‚ SAbs, or both) had a higher risk of CLAD (hazard ratio [95% confidence intervals], 8.787 [1.694-45.567]; P = 0.010) and lower CLAD-free survival after LTx than the control group (P = 0.007); however, overall survival was similar between the 2 groups (P = 0.618). Conclusions. GER was associated with elevated SAbs in LTx candidates, and either GER, SAbs, or both were associated with CLAD in LTx recipients. This association suggests that GER may cause an immune response to normally sequestered lung-associated self-antigens that drives ongoing lung injury.
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (3) , 1065-1073
Bilateral Lung Transplant for a Connective Tissue Disorder: Esophageal Motility and 3-year Survival
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (3) , 1065-1073
Bilateral Lung Transplant for a Connective Tissue Disorder: Esophageal Motility and 3-year Survival
- 1 December 2021
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 25 (12) , 3234-3235
Roux-en-Y with Distal Gastrectomy for Gastroesophageal Reflux After Sleeve Gastrectomy
- 1 December 2021
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 25 (12) , 3234-3235
Roux-en-Y with Distal Gastrectomy for Gastroesophageal Reflux After Sleeve Gastrectomy